atomik labz retatrutide glp-3 30mg GLP-3 RT

Receptors GLP-1 GLP-1 + GIP GLP-1 + GIP + Glucagon Class Single-agonist Dual-agonist Triple-agonist Generation First Second Third Brand Names Ozempic / Wegovy Mounjaro / Zepbound Not yet approved Phase 2 Weight Loss (peak) ~14.9% ~20.9% 24.2% Approval Status FDA approved FDA approved Phase 3 trials A common question: is the difference between 20.9% (tirzepatide) and 24.2% (retatrutide) really that significant

Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: Role of K(ATP) channels

The suit accused Lilly of demonstrating a nationwide pattern of deceptive advertising, saying one of its ad campaigns uses an outdated dose of Novos Wegovy to compare it unfavorably to Lillys Zepbound

Keen to share my findings, I made a post in my Facebook group